Ann: Acrux Submits First-To-File Generic of Jublia, page-15

As anticipated, Bausch Health appealed the FDA's determination that the patent for Jublia was invalid. It was submitted last week, on August 7.

Reading the announcement, it doesn't exactly present a mood of confidence regarding a positive outcome for their shareholders. Despite a policy to "aggressively defend the company's patents and other intellectual property", they appear  resigned that generics will continue to significantly impact revenue. It seems unlikely, in my mind, the FDA will make an about-turn on this decision.

As a side note and to avoid confusion, Bausch Health were formerly Valeant Pharmaceuticals and changed their name last month. One would assume to distance themselves from the drug hike fiasco a couple of years prior.
https://www.marketscreener.com/BAUS...-Condition-and-Results-of-Operation-27074346/